BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38401998)

  • 1. Evidence for molecular subtyping in pancreatic ductal adenocarcinoma: a systematic review.
    Robertson FP; Cameron A; Spiers HVM; Joseph N; Taylor E; Ratnayake B; Jamieson NB; Pandanaboyana S
    HPB (Oxford); 2024 May; 26(5):609-617. PubMed ID: 38401998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
    Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
    Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens.
    Rasmussen LG; Verbeke CS; Sørensen MD; Pfeiffer P; Tan Q; Mortensen MB; Fristrup C; Detlefsen S
    Pancreatology; 2021 Apr; 21(3):530-543. PubMed ID: 33637450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma.
    Birnbaum DJ; Begg SKS; Finetti P; Vanderburg C; Kulkarni AS; Neyaz A; Hank T; Tai E; Deshpande V; Bertucci F; Birnbaum D; Lillemoe KD; Warshaw AL; Mino-Kenudson M; Fernandez-Del Castillo C; Ting DT; Liss AS
    Clin Cancer Res; 2021 Apr; 27(8):2314-2325. PubMed ID: 33547202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping.
    Rao J; Sinn M; Pelzer U; Riess H; Oettle H; Demir IE; Friess H; Jäger C; Steiger K; Muckenhuber A
    J Pathol Clin Res; 2024 May; 10(3):e12377. PubMed ID: 38750616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic cancer survival analysis defines a signature that predicts outcome.
    Raman P; Maddipati R; Lim KH; Tozeren A
    PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
    Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
    Front Immunol; 2021; 12():690056. PubMed ID: 34335594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer.
    Roa-Peña L; Leiton CV; Babu S; Pan CH; Vanner EA; Akalin A; Bandovic J; Moffitt RA; Shroyer KR; Escobar-Hoyos LF
    Sci Rep; 2019 Aug; 9(1):11239. PubMed ID: 31375762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic cancer subtypes: a roadmap for precision medicine.
    Torres C; Grippo PJ
    Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
    Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value.
    Namkung J; Kwon W; Choi Y; Yi SG; Han S; Kang MJ; Kim SW; Park T; Jang JY
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1160-7. PubMed ID: 26644397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
    Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
    Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
    [No Abstract]   [Full Text] [Related]  

  • 15. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
    Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
    Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.
    Puleo F; Nicolle R; Blum Y; Cros J; Marisa L; Demetter P; Quertinmont E; Svrcek M; Elarouci N; Iovanna J; Franchimont D; Verset L; Galdon MG; Devière J; de Reyniès A; Laurent-Puig P; Van Laethem JL; Bachet JB; Maréchal R
    Gastroenterology; 2018 Dec; 155(6):1999-2013.e3. PubMed ID: 30165049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
    George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
    Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
    World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
    Eyres M; Lanfredini S; Xu H; Burns A; Blake A; Willenbrock F; Goldin R; Hughes D; Hughes S; Thapa A; Vavoulis D; Hubert A; D'Costa Z; Sabbagh A; Abraham AG; Blancher C; Jones S; Verrill C; Silva M; Soonawalla Z; Maughan T; Schuh A; Mukherjee S; O'Neill E
    Gastroenterology; 2021 Aug; 161(2):653-668.e16. PubMed ID: 33915173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
    Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.